Myeloma

Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.

Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.

Adding the proteasome inhibitor Kyprolis (carfilzomib) after Revlimid (lenalidomide) in patients with relapsed multiple myeloma showed significant delay of disease progression.

Patients with multiple myeloma fare better with continuous Revlimid (lenalidomide).

Updates from the annual meeting of the American Society of Hematology.

Robert Kyle is changing lives through research.

New treatments for multiple myeloma target the disease in different ways.

The latest in cancer prevention, diagnosis & treatment.

Velcade-based therapy shows benefit in multiple myeloma trial called GIMEMA.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Research into vaccine therapy for cancer is extending to many cancer types.

An introduction to multiple myeloma.

Learn how multiple myeloma is diagnosed.

Learn how multiple myeloma is staged.

Learn about treatment options for multiple myeloma.

The potential side effects and complications of multiple myeloma.

A survivor's story of overcoming fear of myeloma recurrence.

A survivor's story of living with multiple myeloma.

Questions to ask your medical team about multiple myeloma.

The key findings from a phase 3 Spanish study are three-fold: less aggressive initial (induction) therapy with once-weekly—rather than twice-weekly—Velcade (bortezomib) was effective; melphalan outdid thalidomide as a partner to Velcade; and following induction with maintenance therapy may be the best approach for treating multiple myeloma patients over 65 who haven’t received previous treatment.

Updates from the American Society of Hematology meeting and the San Antonio Breast Cancer Symposium.

Monitoring and managing effects of transplantation can be a waiting game.

Advances in stem cell transplantation leads to a changing landscape in treating blood cancers, such as lymphoma, leukemia, and multiple myeloma.

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer.

Velcade is now available for newly diagnosed multiple myeloma patients and new drugs emerge as potential treatment to a serious side effect.

News updates from the American Society of Hematology and the San Antonio Breast Cancer Symposium.

The old and the new in myeloma therapy give patients more options.

Satraplatin's approval review deadline gets pushed back by the FDA and a large clinical trial shows Vidaza extends survival in patients with MDS.

Brian Durie, MD, and Susan Novis, president of the International Myeloma Foundation, answer questions about the progress in multiple myeloma.